172 related articles for article (PubMed ID: 20557841)
1. Neoadjuvant treatment of adenocarcinomas of the gastroesophageal junction and stomach - a feasibility trial combining cisplatin and docetaxel with either 5-fluorouracil or capecitabine.
Schultheis B; Riebeling J; Allali M; Bergmann U; Kummer G; Sendler U; Tannapfel A; Sendler A; Strumberg D
Int J Clin Pharmacol Ther; 2010 Jul; 48(7):451-2. PubMed ID: 20557841
[No Abstract] [Full Text] [Related]
2. Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}.
Thuss-Patience PC; Hofheinz RD; Arnold D; Florschütz A; Daum S; Kretzschmar A; Mantovani-Löffler L; Bichev D; Breithaupt K; Kneba M; Schumacher G; Glanemann M; Schlattmann P; Reichardt P; Gahn B
Ann Oncol; 2012 Nov; 23(11):2827-2834. PubMed ID: 22734012
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group.
Giordano KF; Jatoi A; Stella PJ; Foster N; Tschetter LK; Alberts SR; Dakhil SR; Mailliard JA; Flynn PJ; Nikcevich DA;
Ann Oncol; 2006 Apr; 17(4):652-6. PubMed ID: 16497828
[TBL] [Abstract][Full Text] [Related]
4. Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma.
Goel G; Jauhri M; Negi A; Aggarwal S
Hematol Oncol Stem Cell Ther; 2010; 3(2):55-9. PubMed ID: 20543537
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas.
Lo SS; Khorana AA; Javle M; Simon S; Kiefer G; Rajasenan K; Wang H; Hantel A; Shayne M; Hwang J; Schmotzer A; Ramanathan RK
Oncology; 2010; 78(2):125-9. PubMed ID: 20389134
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer.
Tsai JY; Iannitti D; Berkenblit A; Akerman P; Nadeem A; Rathore R; Harrington D; Roye D; Miner T; Barnett JM; Maia C; Stuart K; Safran H
Am J Clin Oncol; 2005 Aug; 28(4):329-33. PubMed ID: 16062072
[TBL] [Abstract][Full Text] [Related]
7. Can cisplatin and infused 5-fluorouracil be replaced by oxaliplatin and capecitabine in the treatment of advanced oesophagogastric cancer? The REAL 2 trial.
Chong G; Cunningham D
Clin Oncol (R Coll Radiol); 2005 Apr; 17(2):79-80. PubMed ID: 15830568
[No Abstract] [Full Text] [Related]
8. Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer.
Andersen M; Schønnemann KR; Yilmaz M; Jensen HA; Vestermark LW; Pfeiffer P
Acta Oncol; 2010 Nov; 49(8):1246-52. PubMed ID: 20429725
[TBL] [Abstract][Full Text] [Related]
9. Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy.
Lorenzen S; Thuss-Patience P; Al-Batran SE; Lordick F; Haller B; Schuster T; Pauligk C; Luley K; Bichev D; Schumacher G; Homann N
Ann Oncol; 2013 Aug; 24(8):2068-73. PubMed ID: 23592699
[TBL] [Abstract][Full Text] [Related]
10. Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.
Lorenzen S; von Gall C; Stange A; Haag GM; Weitz J; Haberkorn U; Lordick F; Weichert W; Abel U; Debus J; Jäger D; Münter MW
BMC Cancer; 2011 Jun; 11():266. PubMed ID: 21702914
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer.
Di Lauro L; Vici P; Belli F; Tomao S; Fattoruso SI; Arena MG; Pizzuti L; Giannarelli D; Paoletti G; Barba M; Sergi D; Maugeri-Saccà M
Gastric Cancer; 2014 Oct; 17(4):718-24. PubMed ID: 24318671
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer.
Evans D; Miner T; Akerman P; Millis R; Jean M; Kennedy T; Safran H
Am J Clin Oncol; 2007 Aug; 30(4):346-9. PubMed ID: 17762433
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
[TBL] [Abstract][Full Text] [Related]
14. Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Cunningham D; Okines AF; Ashley S
N Engl J Med; 2010 Mar; 362(9):858-9. PubMed ID: 20200397
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India.
Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
Indian J Cancer; 2017; 54(1):47-51. PubMed ID: 29199662
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of cisplatin and capecitabine in combination as first line treatment for unselected patients with advanced gastric cancer.
Viteri A; Muñoz A; Rubio I; Barceló R; Martínez-Bueno A; Fernández R; Carrera S; López-Vivanco G
Acta Oncol; 2007; 46(3):397-9. PubMed ID: 17450479
[No Abstract] [Full Text] [Related]
17. Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial.
Tebbutt NC; Cummins MM; Sourjina T; Strickland A; Van Hazel G; Ganju V; Gibbs D; Stockler M; Gebski V; Zalcberg J;
Br J Cancer; 2010 Feb; 102(3):475-81. PubMed ID: 20068567
[TBL] [Abstract][Full Text] [Related]
18. A pilot trial of FLOT neoadjuvant chemotherapy for resectable esophagogastric junction adenocarcinoma.
Al-Fakeeh A; Ferri L; Mulla N; Doerksen T; Al-Ruzug I; Santos F; Alcindor T
Med Oncol; 2016 Jul; 33(7):62. PubMed ID: 27225939
[TBL] [Abstract][Full Text] [Related]
19. Venous thromboembolism in patients receiving perioperative chemotherapy for esophagogastric cancer.
Khanna A; Reece-Smith AM; Cunnell M; Madhusudan S; Thomas A; Bowrey DJ; Parsons SL
Dis Esophagus; 2014 Apr; 27(3):242-7. PubMed ID: 23651074
[TBL] [Abstract][Full Text] [Related]
20. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
Glatz T; Bronsert P; Schäfer M; Kulemann B; Marjanovic G; Sick O; Hopt UT; Zirlik K; Makowiec F; Hoeppner J
Eur J Surg Oncol; 2015 Oct; 41(10):1300-7. PubMed ID: 26253194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
